WO2020189853A1 - Composition pharmaceutique pour la prévention ou le traitement d'une maladie de la vésicule liée au stress comprenant la myricétine en tant que principe actif - Google Patents

Composition pharmaceutique pour la prévention ou le traitement d'une maladie de la vésicule liée au stress comprenant la myricétine en tant que principe actif Download PDF

Info

Publication number
WO2020189853A1
WO2020189853A1 PCT/KR2019/007498 KR2019007498W WO2020189853A1 WO 2020189853 A1 WO2020189853 A1 WO 2020189853A1 KR 2019007498 W KR2019007498 W KR 2019007498W WO 2020189853 A1 WO2020189853 A1 WO 2020189853A1
Authority
WO
WIPO (PCT)
Prior art keywords
disease
treatment
endoplasmic reticulum
cells
paroxetine
Prior art date
Application number
PCT/KR2019/007498
Other languages
English (en)
Korean (ko)
Inventor
원규장
문준성
카루나카란우다야쿠마르
엘루말레이수마
이지은
Original Assignee
영남대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 영남대학교 산학협력단 filed Critical 영남대학교 산학협력단
Publication of WO2020189853A1 publication Critical patent/WO2020189853A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une composition pour le traitement de maladies de la vésicule liées au stress et la protection de cellules pancréatiques par inhibition d'une réponse de stress vésiculaire par la myricétine, dans laquelle la myricétine inhibe une activation de la phosphatase 5 cycline-dépendante dans une cellule induite pour avoir un stress vésiculaire, augmente significativement l'expression de protéines anti-apoptotiques, et conserve une fonction de sécrétion d'insuline des cellules bêta pancréatiques, et peut donc être utilisée efficacement pour le traitement de maladies de la vésicule liées au stress et la protection de cellules pancréatiques.
PCT/KR2019/007498 2019-03-18 2019-06-21 Composition pharmaceutique pour la prévention ou le traitement d'une maladie de la vésicule liée au stress comprenant la myricétine en tant que principe actif WO2020189853A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20190030698 2019-03-18
KR10-2019-0030698 2019-03-18

Publications (1)

Publication Number Publication Date
WO2020189853A1 true WO2020189853A1 (fr) 2020-09-24

Family

ID=72519336

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2019/007498 WO2020189853A1 (fr) 2019-03-18 2019-06-21 Composition pharmaceutique pour la prévention ou le traitement d'une maladie de la vésicule liée au stress comprenant la myricétine en tant que principe actif

Country Status (1)

Country Link
WO (1) WO2020189853A1 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150101788A (ko) * 2014-02-27 2015-09-04 인제대학교 산학협력단 미리세틴을 유효성분으로 포함하는 췌장 리파아제 저해용 조성물
CN107721959A (zh) * 2016-08-12 2018-02-23 青岛海洋生物医药研究院股份有限公司 杨梅素衍生物及制备方法，及其在治疗结肠炎、防治结肠炎癌转化和治疗结直肠癌中的应用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150101788A (ko) * 2014-02-27 2015-09-04 인제대학교 산학협력단 미리세틴을 유효성분으로 포함하는 췌장 리파아제 저해용 조성물
CN107721959A (zh) * 2016-08-12 2018-02-23 青岛海洋生物医药研究院股份有限公司 杨梅素衍生物及制备方法，及其在治疗结肠炎、防治结肠炎癌转化和治疗结直肠癌中的应用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KARUNAKARAN, U. ET AL.: "Myricetin protects against high glucose-induced beta- cell apoptosis by attenuating endoplasmic reticulum stress via inactivation of cyclin-dependent kinase 5", 2018 ASIA ISLET BIOLOGY & INCRETIN SYMPOSIUM (AIBIS, 2 August 2018 (2018-08-02), XP055741209 *
LI, YONG ET AL.: "Minireview: Therapeutic potential of myricetin in diabetes mellitus", FOOD SCIENCE AND HUMAN WELLNESS, vol. 1, 2012, pages 19 - 25, XP055741204 *
WANG, FENG ET AL.: "M10, a novel derivative of Myricetin, prevents ulcerative colitis and colorectal tumor through attenuating robust endoplasmic reticulum stress", CARCINOGENESIS, vol. 39, no. 7, 2018, pages 889 - 899, XP055741205 *

Similar Documents

Publication Publication Date Title
Tang et al. Antitumor and antiplatelet activity of alkaloids from veratrum dahuricum
Qi et al. Norisoboldine, a natural aryl hydrocarbon receptor agonist, alleviates TNBS-induced colitis in mice, by inhibiting the activation of NLRP3 inflammasome
WO2015130109A1 (fr) Composition pharmaceutique pour le traitement du cancer contenant du gossypol et de la phénformine en tant que principes actifs
Na et al. Protective effect of isoliquiritigenin against ethanol-induced hepatic steatosis by regulating the SIRT1-AMPK pathway
WO2017014331A1 (fr) Composition contenant du nad pour la prévention et le traitement de l'obésité ou d'une tolérance au glucose altérée
US20230414675A1 (en) Use of anti-aging glycopeptides to enhance pancreatic cell health, survival and improve transplant outcome
da Luz et al. Ultrastructural analysis of Leishmania infantum chagasi promastigotes forms treated in vitro with usnic acid
WO2020189853A1 (fr) Composition pharmaceutique pour la prévention ou le traitement d'une maladie de la vésicule liée au stress comprenant la myricétine en tant que principe actif
Takii et al. Insulinotropic and anti-apoptotic effects of nobiletin in INS-1D β-cells
Kongthitilerd et al. Cyanidin-3-rutinoside stimulated insulin secretion through activation of L-type voltage-dependent Ca2+ channels and the PLC-IP3 pathway in pancreatic β-cells
KR0145412B1 (ko) 항염증성 조성물, 항알레르기성 조성물 또는 이들 혼합 성질의 조성물
WO2012033235A1 (fr) Composition pharmaceutique pour le traitement d'un trouble de l'anxiété, contenant de la n-acétyl-l-cystéine ou un dérivé de celle-ci
WO2020116742A1 (fr) Benzimidazole ou dérivés de benzimidazole permettant de prévenir et de traiter une maladie du système nerveux central, le diabète et leurs complications
Li et al. Kaempferol regulates mir-15b/bcl-2/tlr4 to alleviate ogd-induced injury in h9c2 cells
WO2011046381A2 (fr) COMPOSITION D'INHIBITION DE TGF-β COMPRENANT DES DÉRIVÉS D'IMIDAZOPURINE
Li et al. Procyanidin B2 alleviates palmitic acid-induced injury in HepG2 cells via endoplasmic reticulum stress pathway
WO2018080276A1 (fr) Composition pharmaceutique destinée à prévenir ou à traiter une lésion d'ischémie-reperfusion, contenant de l'acide biliaire
Zhang et al. Oridonin induces apoptosis in human nasopharyngeal carcinoma cells involving ROS generation.
WO2020189937A2 (fr) Antibiotiques réorientés pour la chimiothérapie génotoxique non nucléaire et composition pharmaceutique pour un anti-cancereux contenant ceux-ci
Li et al. DUSP9 alleviates hepatic ischemia/reperfusion injury by restraining both mitogen-activated protein kinase and IKK in an apoptosis signal-regulating kinase 1-dependent manner: Role of DUSP9 in hepatic ischemia/reperfusion injury
WO2014051359A1 (fr) Composition pharmaceutique comprenant de la néférine comme ingrédient actif de prévention contre un hépatome ou de traitement de ce dernier
KR20160101634A (ko) TNP(N2-(m-Trifluorobenzyl), N6-(p-nitrobenzyl)purine)를 유효성분으로 함유하는 아세트아미노펜 유래 간 독성 예방 및 치료용 조성물
WO2016190480A1 (fr) Procédé de criblage d'agent de contrôle de la fission mitochondriale
WO2017069376A1 (fr) Composition pour le traitement de maladies inflammatoires contenant un inhibiteur de ikkε
WO2022025709A1 (fr) Utilisation préventive, de soulagement ou thérapeutique de composé thiophène 2,3,5-substitué contre une tumeur stromale gastro-intestinale

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19920532

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19920532

Country of ref document: EP

Kind code of ref document: A1